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Summary Many patients with Stage 1 non-seminomas are now treated by orchidectomy and close follow-up
along. Chart review indicated that a group of such patients, compared with patients treated with chemo-
therapy, tended to be less compliant with follow-up. A questionnaire given to a second sample of patients
confirmed that surgical patients underestimated the dangers of the disease and chances of relapse, and doubted
the value of follow-up.
In the last two decades developments in diagnostic tech-
niques and chemotherapy for nonseminomatous testicular
cancer have resulted in very high cure rates (e.g. Pizzocaro et
al., 1986; Sogani et al., 1984). There is a recent trend towards
treating patients with Stage 1 tumours by orchidectomy alone
and reserving further treatment for those who relapse (ibid).
If relapse is detected soon enough the majority of these
patients will be cured by appropriate chemotherapy. Most
patients presenting with metastatic disease can also be cured.
If relapse occurs after surgery or chemotherapy, it tends to
do so generally within 2 years. The risk of relapse is 20-30%
for patients treated with surgery alone, compared with less
than 10% for those in complete remission after chemo-
therapy for all but advanced metastatic disease (ibid). Cure is
still possible for some patients relapsing after first-line
chemotherapy.
It is therefore important that patients in both categories,
but particularly those treated by surgery alone, should have
regular follow-up with clinical examination, radiological
examination, and tumour marker studies as appropriate.
We have observed that patients treated with surgery alone
seem to keep follow-up appointments less often than those
treated with chemotherapy (Young et al., 1989). The present
study attempts to confirm this observation and to determine
by questionnaire the reason for noncompliance.
Patients and methods
An initial chart review sample comprised 25 adult patients
with non-seminomas being followed after orchidectomy alone
(11 patients) or chemotherapy (14 patients). All patients were
followed exclusively at this centre for over a year, had only
one primary and were referred within 2 months of orchidec-
tomy. A second sample of 27 patients meeting the above
criteria completed a questionnaire.
Chart review
Three compliance measures were derived from charts: (1) The
total number of visits made was compared with the total
number of appointments and/or investigations booked. Any
hospitalisation was counted as one instance of compliance,
(2) The number of times the patient was examined or tested
at intervals of 6 weeks or less was computed over 1 year, (3)
The number of monthly appointments actually scheduled.
Questionnaire study
A questionnaire was developed which measured beliefs about
testicular cancer concerning (a) its severity, (b) the chances of
recurrence or spread, (c) the benefits of follow-up and (d)
difficulties with coming for follow-up (Table I). Items 2, 3, 7
and 9 were adapted from questions (in colloquial North
American English) developed and tested in a number oflarge
clinical studies in the USA (Leventhal et al., 1986; Stillman,
1977). Items 2 and 3 were designed to show whether patients
believed their disease was local or wide spread.
Patients were approached to give informed consent on
their regularly scheduled clinic appointment. All patients in
the chemotherapy group had completed their treatment. No
patients refused to take part in the study.
Results
Chart review
More than halfofthose treated by chemotherapy (57%) were
100% compliant with appointments and only a small propor-
tion (14%) fell below 80% compliance. None of the surgery
only group were 100% compliant, and 57% were less than
80% compliant. Patients treated with chemotherapy kept
almost all (92.8%) of their appointments, while surgical
patients kept only 77% (t = 3.52, d.f. = 20.8, P = 0.0021).
Patients treated with chemotherapy were examined on the
average of 10.0 of the 12 months. Surgery only patients were
seen during an average of 8.36 months in the same 12 month
period (t = 2.29, d.f. = 21.1, P = 0.032). Patients treated with
chemotherapy were seen during more of the first 6 months
than the group treated by surgery alone (means of 5.4 vs 4.4),
but the difference is still significant during the second half of
the 12 months after surgery (4.6 vs 4.0, t = 2.29, d.f. = 21.9,
P = 0.032). Almost the same results are obtained when
adherence to monthly visits is measured for a year after
chemotherapy and compared with the year after orchidec-
tomy for the surgery alone group (t = 2.37, d.f. = 21.1,
P = 0.027). Surgery alone patients had a mean of 91% of the
required appointments scheduled and chemotherapy patients
had a mean of 85% (t = 0.56, d.f. = 22.6, P = 0.58).
Questionnaire study
Only the results from questions with rating scales or forced
choices are included here. Open ended questions generally
produced unratable anecdotal answers. The 12 objective
questions fell into four groups concerning perceptions of
illness severity, susceptibility to relapse and the benefits and
difficulties of the watch and wait protocol. Mean or modal
choices for each treatment group are shown in Table I.
Correspondence: B.J. Young, Department of Psychology, Alberta
Hospital, Box 307, Edmonton, Alberta, Canada T5J 2J7.
Received 29 November 1990; and in revised form 8 May 1991.
Br. J. Cancer (1991), 64, 606-608 '." Macmillan Press Ltd., 1991COMPLIANCE WITH FOLLOW-UP FOR TREATMENT OF NONSEMINOMAS 607
Patients treated only by surgery did not think that they
were any more likely to relapse than patients treated by
chemotherapy. There was a nonsignificant trend for chemo-
Table I Questions about the severity of testicular cancer (1-3),
chances of relapse (4-6), benefits (7-9) and difficulties (10-12) of
coming for follow-up examinations
(1) How dangerous do you think your cancer is?
no danger extremely dangerous
(S) (C)
1 2 3 4 5
(2) There seems to be three kinds of illness:
(a) there is onewhere you get sick, take some treatment, and it goes
away for good like appendicitis {S) (C)
(b) another comes and goes every so often, like an allergy
(c) the third kind stays with you all the time, like diabetes
Which one would you say your testicular canceris like? (check one)
(3) Some people think:
(a) all the cancer is got initially {S)
(b) others think something is still present in certain areas
(c) others think it was in certain areas and might be
elsewhere (C)
(d) others think it is quite widespread
What do you think? (check one).
(4) How likely is it that your disease will get worse or come back?
not likely very likely
(S)
(C)
1 2 3 4 5
(5) Ifyou failtoattend theclinicforfollow-upappointments andscans,
howlikelydoyou think it will be thatyourillness willcomeback
or get worse?
not likely very likely
(C) (S)
1 2 3 4
(6) Do you think your cancer will get worse or better?
worse better
(C) {S)
1 2 3 4 5
(7) What is your understanding ofwhy you are coming for follow-up
appointments and scans and blood tests? (check one)
(a) it will not help
(b) cancer will be delayed or slowed down
(c) cancer can be controlled or stopped if it recurs (C) (S)
(d) cancer can be made to go into remission again
(e) a relapse can be prevented
(f) the cancer can be cured
(g) don't know
(8) Howeffectivedoyouthinkyourfollow-up appointments, scansand
blood tests will be to help your cancer?
not effective at all extremely effective
(S) (C)
1 2 3 4 5
(9) Whether they find a recurrence ofcancer or not in a test does not
matter because by then it's too late (check one)
(1) strongly agree
(2) agree a little
(3) disagree a little (C) (S)
(4) disagree strongly
(10) Even though it's a good idea I find coming for further follow-up
appointments too difficult
(1) strongly agree
(2) agree a little
(3) disagree a little (S)
(4) disagree strongly (C)





1 2 3 4 5
(12) How much disruption does coming for follow-up clinic appoint-
ments and scans cause you in your work or social life?
not at all high disruption
(C) (S)
1 2 3 4
therapy patients (87.5% vs 54%) to see follow-up as more
beneficial.
The relationship between the treatment group, difficulty in
attending for follow-up, and perceptions of disease severity
were examined by means of Fisher's exact test. All patients
treated only by surgery found it difficult to come for follow
up visits (P=<0.001) (because, for example, of the upset
caused to family members and their own anxiety about
visiting the clinic). Less clear results were obtained for the
questions concerned with perceptions of disease severity.
More of the patients treated by chemotherapy rated their
disease as extremely dangerous than patients treated only by
surgery (P = 0.0473). The two groups did not differ signifi-
cantly in whether they saw their disease as local of wide-
spread (P= 0.2638) on questions 2 and 3.
Although there was a trend for chemotherapy patients to
choose answers suggesting they saw their disease as wide-
spread, about half of the surgery alone patients also held this
view.
Could any statistical relationship be shown between beliefs
about the severity of the disease and perceptions of the
difficulties of follow up? There is a trend for patients who did
not see testicular cancer as dangerous to see coming for
follow up as more of a nuisance, but the significance is
borderline (P = 0.0578). The relationship between perceptions
of the danger of the disease and the type of disease model
was not significant (P = 0.70). Among those whom saw the
disease as dangerous, however, twice as many believed their
disease was widespread.
Discussion
The results of the chart review suggest that testicular cancer
patients treated by surgery alone are less compliant than
those treated with chemotherapy. Given the small sample
sizes these results clearly require further validation in a pro-
spective study with a larger sample size. However, the ques-
tionnaire study with a separate sample of patients and a
different method also confirms that surgical patients saw
follow-up as a nuisance. The greater tendency of
chemotherapy patients to come for follow-up is apparent not
only during their chemotherapy, but also persists long past
the end of chemotherapy. Problems with compliance cannot
reflect possible aversive effects of treatment (depression, emo-
tional upset and sexual dysfunction) since these would be
expected to be worse for patients receiving chemotherapy.
The questionnaire study sheds some light on the difference
in compliance between the two groups. Chemotherapy
patients tended to see their disease as more dangerous than
surgical patients. Of course, chemotherapy patients did start
with more advanced disease and the unpleasantness of the
chemotherapy would be expected to reinforce disease
severity. However, the low estimate of danger by surgical
patients is very unrealistic because their chance of relapse is
much higher.
In this study, the perceived danger of the disease is not
closely related to whether the patient believed the disease was
localised or widespread (unlike the findings of Leventhal et
al., for breast cancer patients). This may reflect the
conflicting information patients seem to receive about tes-
ticular cancer, that it is 'serious but curable' disease, which
fails to emphasise that the cure is possible only with appro-
priate treatment at the right time.
The cost to the patient who relapses of failure to keep
follow-up appointments will vary depending on just how
noncompliant he is. Some patients may require more
chemotherapy to cure their disease or even be rendered
incurable in the extreme case. Are there ways of reducing this
possibility? Insufficient attention appears to be paid in our
institution to educating patients about the value of a surveil-
lance policy. Optimism may be interpreted by the patient as
implying that they do not need to do very much to avert the
possibility of relapse. The surveillance policy has spared the
majority of young men with testicular cancer the morbidity
Also shown are mean (rating scales) and modal responses (multiple
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patients (C).608 B.J. YOUNG et al.
of lymph node dissection or prophylactic radiation therapy.
However, the success of this policy is critically dependent on
patient compliance and it seems that this can only be im-
proved by better patient education. Our future efforts will be
directed at developing and evaluating tools to achieve this.
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